The sNDA is supported by data from the phase 3 ENERGIZE and ENERGIZE-T studies, which evaluated mitapivat vs placebo in patients with NTD and TD alpha- or beta-thalassemia, respectively.

HealthDay News — Eight in 10 infants received respiratory syncytial virus (RSV) protection during the 2023 to 2024 season, according to a research letter published online January 8 in JAMA Network ...

Multidisciplinary collaborative approach to care is required for patients with hematological malignancies in pregnancy.

Meaningful reduction in symptoms seen for some taking an extended course outside of the context of an acute infection ...

Morning-type pattern significantly linked to lower risks for all-cause and cardiovascular disease-specific mortality compared with non-coffee drinking ...